KPV

What it is

KPV is a three-amino-acid peptide, Lys-Pro-Val, derived from the C-terminal region of alpha-melanocyte-stimulating hormone^{[6 ,10 ]}. Alpha-MSH and related melanocortin peptides have long been studied for immunomodulatory and anti-inflammatory activity, and KPV is one of the shortest fragments investigated for retaining some of those effects^{[6 ,10 ]}.

At the biological level, KPV has been studied in inflammatory signaling rather than as a hormone-replacement therapy. Experimental work has investigated whether KPV can reduce inflammatory mediator production, inhibit NF-kappaB-related pathways, alter epithelial-cell responses, or act through melanocortin receptor-related mechanisms^{[6 –11 ]}. The pathway biology is not fully reducible to one receptor or one disease model.

Popular peptide discourse often frames KPV as a “gut healing” or “anti-inflammatory” peptide. The research basis for those phrases is mostly preclinical, including murine inflammatory bowel disease models and nanoparticle delivery systems designed to target inflamed intestinal tissue^{[9 ,12 ]}. No FDA-approved KPV product exists for inflammatory bowel disease, wound healing, dermatology, allergy, autoimmune disease, or any other indication.

KPV has been studied in vitro and in animal models using route-specific experimental delivery systems, including targeted oral nanoparticle delivery in a mouse colitis model^{[12 ]}. This page does not provide dosing, route, or compounding guidance.

Regulatory status

KPV is not FDA-approved in the United States. No FDA-approved KPV prescribing label was identified for any indication during this review.

503A status — withdrawn nomination, PCAC consultation pending

FDA’s 503A page states that state-licensed physicians and pharmacists may compound using bulk drug substances only if the substance meets a USP/NF monograph pathway, is a component of an FDA-approved drug product when no monograph exists, or appears on FDA’s 503A bulks list^{[1 ]}. KPV is not listed in 503A Category 1 or on the 503A bulks list in FDA’s April 22, 2026 category document^{[2 ]}.

FDA’s April 22, 2026 category document states that KPV was removed from Category 2 because the nomination was withdrawn, but FDA announced that it intends to consult PCAC on July 23, 2026 regarding potential inclusion of KPV-related bulk drug substances, including KPV acetate and KPV free base, on the 503A bulks list^{[2 ]}. Until FDA completes that process and updates the relevant lists or rules, this draft treats KPV as not currently available through FDA-compliant routine compounding channels.

FDA safety statement

FDA’s significant-safety-risk page states that FDA has not identified human exposure data for drug products containing KPV administered by any route and lacks important information about whether KPV would cause harm in humans^{[4 ]}. That is a regulatory safety statement, not a conclusion that KPV is proven harmful.

503B and controlled-substance status

For 503B outsourcing facilities, FDA states that a bulk drug substance must be on the 503B bulks list or the compounded drug must appear on FDA’s shortage list at the relevant time^{[3 ]}. No 503B pathway for KPV was identified. KPV is not listed in federal controlled-substance schedules in 21 CFR Part 1308 as reviewed on May 7, 2026^{[5 ]}.

Research summary

KPV’s research base begins with melanocortin pharmacology. Getting, Schioth, and Perretti dissected the anti-inflammatory effects of core and C-terminal alpha-MSH peptides and examined KPV as a short sequence with anti-inflammatory potential^{[6 ]}. Elliott and colleagues investigated alpha-MSH, KPV, and ACTH signaling in human keratinocyte cells, providing dermatology-relevant mechanistic data rather than clinical efficacy data^{[7 ]}.

NF-kappaB and bronchial epithelial mechanisms

NF-kappaB-related mechanisms are a recurring theme. Kelly and colleagues reported that immobilized alpha-MSH 10-13 inhibited TNF-alpha-stimulated NF-kappaB activity^{[8 ]}. Land later studied melanocortin-related peptides in human bronchial epithelial cells and reported inhibition of inflammation cues, with discussion of MC3R agonist roles^{[11 ]}. These studies support plausible anti-inflammatory biology but do not establish patient outcomes.

Inflammatory bowel disease models

Inflammatory bowel disease models are the main source of “gut” claims. Kannengiesser and colleagues reported that KPV had anti-inflammatory potential in murine models of inflammatory bowel disease^{[9 ]}. Xiao and colleagues later used hyaluronic acid-functionalized nanoparticles for oral targeted KPV delivery and reported alleviation of ulcerative-colitis-like inflammation in mice^{[12 ]}. These animal-delivery studies are promising for drug-development research but cannot be interpreted as evidence that oral KPV sold online treats ulcerative colitis or Crohn disease in humans.

Wound-healing claims

Cutaneous and wound-related claims are more indirect. Melanocortin peptides, including KPV-related fragments, have been discussed as future therapeutics for cutaneous wound healing^{[13 ]}. That review-level discussion should not be converted into claims that KPV heals wounds in humans, because clinical trial evidence for KPV itself was not identified.

Where the evidence ends

The evidence base has a major gap: no large randomized clinical trials of KPV in humans were identified as of May 7, 2026. FDA’s compounding safety page also states that it has not identified human exposure data for drug products containing KPV by any route^{[4 ]}. The quality-of-evidence assessment is therefore preclinical and mechanistic only.

Route of administration is a central limitation. The oral nanoparticle study used a targeted delivery system intended to concentrate KPV at inflamed intestinal tissue in an animal model^{[12 ]}. That cannot be extrapolated to ordinary oral capsules, subcutaneous injections, nasal sprays, or topical products. Different routes would have different absorption, degradation, distribution, sterility, and safety issues.

Several common claims remain unsubstantiated. No controlled human trial was identified showing that KPV induces remission in ulcerative colitis, prevents Crohn disease flares, repairs “leaky gut,” reduces systemic inflammation, or improves skin healing. Those claims should be kept out of the editorial research summary unless future human trials support them.

KPV should also be distinguished from broader melanocortin biology. Alpha-MSH and melanocortin receptors have a substantial scientific literature, but KPV is a specific short fragment with its own evidence limitations^{[6 ,10 ]}. A study of a related melanocortin agonist, full alpha-MSH, or an immobilized peptide construct does not automatically establish the activity of soluble KPV in humans^{[6 –11 ]}.

Public discourse

No qualifying public-discourse entries were identified for this page. Search results were dominated by clinic pages, vendors, podcast-adjacent marketing pages, and anonymous social media discussion. No accessible named-source podcast, article, or transcript with a verifiable quote meeting the page standard was identified.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Because KPV is not an FDA-approved drug, there is no FDA-reviewed adverse-event table, contraindication list, drug-interaction profile, or pregnancy/lactation guidance. This should be stated plainly because preclinical anti-inflammatory activity is sometimes mistaken for clinical safety.

FDA: absence of human exposure data

FDA’s safety concern is absence of adequate human exposure information. FDA states that it has not identified human exposure data for drug products containing KPV administered by any route and lacks important information about whether KPV would cause harm in humans^{[4 ]}.

Theoretical risks

Theoretical risks include immune modulation in people with infection, autoimmune disease, inflammatory bowel disease, malignancy, or concurrent immunomodulating drugs. These risks are theoretical and route-dependent, but they are clinically relevant because KPV is often promoted for inflammatory conditions in which patients may already be using prescription immunosuppressants.

Product-quality risks

Product-quality risks are substantial for non-approved peptides: uncertain identity, sterility, endotoxin contamination, degradation, aggregation, salt-form ambiguity, and inaccurate labeling. These concerns are especially important for injectable products, but oral or topical products are not automatically safe.

Patients interested in KPV often have inflammatory bowel disease, autoimmune disease, or chronic wounds, which are medically complex conditions with evidence-based therapies and meaningful risks from delayed treatment. The absence of human KPV data is therefore not a minor technicality; it is central to patient safety and claim substantiation.

Available through

KPV is not currently available through FDA-compliant prescription or compounding channels in the United States as of 2026-05-07^{[1 –4 ]}. ProPeptideGuide does not link to or endorse grey-market vendors.